Evidence map›Paper›PMID 35216056›Full record

ArticleInternational journal of molecular sciences2022

Loss of Detection of sgN Precedes Viral Abridged Replication in COVID-19-Affected Patients-A Target for SARS-CoV-2 Propagation.

Veronica Ferrucci, Pasqualino de Antonellis, Fabrizio Quarantelli, Fatemeh Asadzadeh, Francesca Bibbò, Roberto Siciliano, Carmen Sorice, Ida Pisano, Barbara Izzo, Carmela Di Domenico and 21 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors at 6 institutions in 1 country.

Veronica FerrucciCEINGE Biotecnologie Avanzate, 80145 Naples, Italy.ORCID 0000-0002-2019-6501
Pasqualino de AntonellisCEINGE Biotecnologie Avanzate, 80145 Naples, Italy.
Fabrizio QuarantelliDipartimento di Medicina Molecolare e Biotecnologie Mediche (DMMBM), University of Naples Federico II, 80131 Naples, Italy.ORCID 0000-0003-0744-5734
Fatemeh AsadzadehCEINGE Biotecnologie Avanzate, 80145 Naples, Italy.
Francesca BibbòCEINGE Biotecnologie Avanzate, 80145 Naples, Italy.
Roberto SicilianoCEINGE Biotecnologie Avanzate, 80145 Naples, Italy.
Carmen SoriceCEINGE Biotecnologie Avanzate, 80145 Naples, Italy.
Ida PisanoCEINGE Biotecnologie Avanzate, 80145 Naples, Italy.
Barbara IzzoCEINGE Biotecnologie Avanzate, 80145 Naples, Italy.
Carmela Di DomenicoCEINGE Biotecnologie Avanzate, 80145 Naples, Italy.
Angelo BocciaCEINGE Biotecnologie Avanzate, 80145 Naples, Italy.
Maria VargasDepartment of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples Federico II, 80131 Naples, Italy.
Biancamaria PierriIstituto Zooprofilattico Sperimentale del Mezzogiorno, 80055 Naples, Italy.ORCID 0000-0001-5248-3014
Maurizio ViscardiIstituto Zooprofilattico Sperimentale del Mezzogiorno, 80055 Naples, Italy.
Sergio BrandiIstituto Zooprofilattico Sperimentale del Mezzogiorno, 80055 Naples, Italy.
Giovanna FuscoIstituto Zooprofilattico Sperimentale del Mezzogiorno, 80055 Naples, Italy.
Pellegrino CerinoIstituto Zooprofilattico Sperimentale del Mezzogiorno, 80055 Naples, Italy.
Livia De PietroU.O.C. Pneumologia, Ospedale Boscotrecase-Asl Napoli3 Sud, 80042 Naples, Italy.
Ciro FurfaroDipartimento di Medicina di Laboratorio e Anatomia Patologica, Nola Hospital, Asl Napoli 3 Sud, 80035 Naples, Italy.
Leonardo Antonio NapolitanoDipartimento di Medicina di Laboratorio e Anatomia Patologica, Nola Hospital, Asl Napoli 3 Sud, 80035 Naples, Italy.
Giovanni PaolellaCEINGE Biotecnologie Avanzate, 80145 Naples, Italy.
Lidia FestaUnità Speciale di Continuità Assistenziale (USCA), Asl Benevento, 82100 Benevento, Italy.
Stefania MarzinottoDipartimento di Medicina di Laboratorio, Università degli Studi di Udine, 33100 Udine, Italy.
Maria Concetta ConteUnità Speciale di Continuità Assistenziale (USCA), Asl Benevento, 82100 Benevento, Italy.
Ivan GentileDipartimento di Medicina Clinica e Chirurgia, University of Naples Federico II, 80131 Naples, Italy.ORCID 0000-0002-5199-8451
Giuseppe ServilloDepartment of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples Federico II, 80131 Naples, Italy.
Francesco CurcioDipartimento di Medicina di Laboratorio, Università degli Studi di Udine, 33100 Udine, Italy.ORCID 0000-0002-9070-4807
Tiziana de CristofaroIEOS-Institute of Experimental Endocrinology and Oncology G. Salvatore, National Research Council, 80131 Naples, Italy.ORCID 0000-0003-0121-0002
Francesco BroccoloLaboratory of Molecular Microbiology and Virology, School of Medicine, University of Milano-Bicocca, 20900 Monza, Italy.ORCID 0000-0002-9737-0459
Ettore CapoluongoCEINGE Biotecnologie Avanzate, 80145 Naples, Italy.
Massimo ZolloCEINGE Biotecnologie Avanzate, 80145 Naples, Italy.ORCID 0000-0002-0970-7243
Ceinge Biotecnologie Avanzate (Italy) · ITIstituto Zooprofilattico Sperimentale del Mezzogiorno · ITUniversity of Naples Federico II · ITUniversity of Udine · ITInstitute for Experimental Endocrinology and Oncology · ITUniversity of Milano-Bicocca · IT

Funding

AIRC 22129PRIN 2017FNZRN3Regione Campania D64I200003800
6 · The paper itself

Abstract

The development of prophylactic agents against the SARS-CoV-2 virus is a public health priority in the search for new surrogate markers of active virus replication. Early detection markers are needed to follow disease progression and foresee patient negativization. Subgenomic RNA transcripts (with a focus on sgN) were evaluated in oro/nasopharyngeal swabs from COVID-19-affected patients with an analysis of 315 positive samples using qPCR technology. Cut-off Cq values for sgN (Cq < 33.15) and sgE (Cq < 34.06) showed correlations to high viral loads. The specific loss of sgN in home-isolated and hospitalized COVID-19-positive patients indicated negativization of patient condition, 3-7 days from the first swab, respectively. A new detection kit for sgN, gene E, gene ORF1ab, and gene RNAse P was developed recently. In addition, in vitro studies have shown that 2'-

Indexed as

Coronavirus Nucleocapsid ProteinsCOVID-19Giant CellsHEK293 CellsHumansLimit of DetectionNasopharynxPhosphoproteinsRibonuclease PRNA, AntisenseRNA, ViralSARS-CoV-2Sensitivity and SpecificitySocial IsolationViral LoadViroporin ProteinsCoronavirus Nucleocapsid ProteinsE protein, SARS coronavirusnucleocapsid phosphoprotein, SARS-CoV-2PhosphoproteinsRibonuclease PRNA, AntisenseRNA, ViralViroporin Proteins2′-O-methyl antisense RNAqPCR methodsSARS-CoV-2 virus particlessgEsgN

Identifiers

PMID35216056
PMCPMC8878976
OpenAlexW4211063431

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.